Novartis said it has made significant progress in the ongoing strategic review of Alcon, and could take a final decision on whether to keep it, or not, by June next year. As previously reported, the group announced in early 2017 that it could sell or spin off its eye care ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.